Prevalence of Primary Aldosteronism in Newly Diagnosed Hypertensive Patients in Primary Care

Abstract

Context Primary aldosteronism (PA) represents the most frequent cause of endocrine arterial hypertension. PA is also common in patients with mild forms of hypertension and normokalemia.

Objective To identify the prevalence of PA in newly diagnosed hypertensive patients in primary care in Southern Germany.

Patients and methods Newly diagnosed hypertensive patients in 27 primary care centers in Munich agreed to participate in the study. Patients were screened for PA using the aldosterone-to-renin ratio (ARR). In case of elevated ARR, confirmation testing was performed. After the diagnosis of PA, subtype differentiation and subsequent therapy of PA were initiated.

Results A total of 235 patients with newly discovered arterial hypertension were initially screened for PA. Among these, 35 were excluded because the medication indicated pre-existing treated arterial hypertension or they were on interfering antihypertensive medication. At the first screening, 2.0% of the patients had hypokalemia. Of the 200 patients with newly discovered arterial hypertension, 42 had an elevated ARR. The incidence of the presence of hypokalemia did not differ according to normal or pathological ARR. Nine patients (21%) did not show up for further testing and were lost to follow-up, and 33 patients underwent a saline infusion test. Of these, 11 patients were diagnosed with PA, leading to at least 5.5% prevalence of PA in the collective. None of the diagnosed PA patients was hypokalemic at screening.

Conclusion A 5.5% prevalence of PA was observed in our data of untreated newly diagnosed patients with hypertension.

Key words

aldosterone - adrenal - renin - secondary hypertension

Publication History

Received: 18 February 2022
Received: 05 September 2022

Accepted: 07 September 2022

Accepted Manuscript online:
07 September 2022

Article published online:
08 November 2022

• References

• 1 Yang Y, Reincke M, Williams TA. Prevalence, diagnosis and outcomes of treatment for primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2020; 34: 101365 DOI: 10.1016/j.beem.2019.101365.
• 2 Monticone S, D’Ascenzo F, Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 41-50 DOI: 10.1016/S2213-8587(17)30319-4.
• 3 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916 DOI: 10.1210/jc.2015-4061.
• 4 Meng Z, Dai Z, Huang K. et al. Long-term mortality for patients of primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Front Endocrinol (Lausanne) 2020; 11: 121 DOI: 10.3389/fendo.2020.00121.
• 5 Hundemer GL, Curhan GC, Yozamp N. et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6: 51-59 DOI: 10.1016/S2213-8587(17)30367-4.
• 6 Rossi GP, Maiolino G, Flego A. et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 2018; 71: 585-591 DOI: 10.1161/HYPERTENSIONAHA.117.10596.
• 7 Buffolo F, Monticone S, Tetti M. et al. Primary aldosteronism in the primary care setting. Curr Opin Endocrinol Diabetes Obes 2018; 25: 155-159 DOI: 10.1097/MED.0000000000000408.
• 8 Mulatero P, Monticone S, Burrello J. et al. Guidelines for primary aldosteronism: Uptake by primary care physicians in Europe. J Hypertens 2016; 34: 2253-2257 DOI: 10.1097/HJH.0000000000001088.
• 9 Mancia G, Fagard R, Narkiewicz K. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219 DOI: 10.1093/eurheartj/eht151.
• 10 Funder JW, Carey RM, Fardella C. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
• 11 Fischer E, Adolf C, Pallauf A. et al. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrinol Metab 2013; 98: 2513-2520 DOI: 10.1210/jc.2012-3934.
• 12 Fischer E, Hanslik G, Pallauf A. et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab 2012; 97: 3965-3973 DOI: 10.1210/jc.2012-2234.
• 13 Betz MJ, Degenhart C, Fischer E. et al. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. Eur J Endocrinol 2011; 165: 301-306 DOI: 10.1530/EJE-11-0287.
• 14 Vonend O, Ockenfels N, Gao X. et al. Adrenal venous sampling: Evaluation of the German Conn’s registry. Hypertension 2011; 57: 990-995 DOI: 10.1161/HYPERTENSIONAHA.110.168484.
• 15 Kanaan E, Haase M, Vonend O. et al. Aldosterone-mediated sodium retention is reflected by the Serum Sodium to Urinary Sodium to (Serum Potassium)(2) to Urinary Potassium (SUSPPUP) index. Diagnostics (Basel) 2020; 10 DOI: 10.3390/diagnostics10080545.
• 16 Jaffe G, Gray Z, Krishnan G. et al. Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension 2020; 75: 650-659 DOI: 10.1161/HYPERTENSIONAHA.119.14359.
• 17 Cohen JB, Cohen DL, Herman DS. et al. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: A retrospective cohort study. Ann Intern Med 2020; DOI: 10.7326/M20-4873..
• 18 Monticone S, Burrello J, Tizzani D. et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811-1820 DOI: 10.1016/j.jacc.2017.01.052.
• 19 Mosso L, Carvajal C, Gonzalez A. et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165 DOI: 10.1161/01.HYP.0000079505.25750.11.
• 20 Calhoun DA, Nishizaka MK, Zaman MA. et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896 DOI: 10.1161/01.hyp.0000040261.30455.b6.
• 21 Rossi GP, Bernini G, Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300 DOI: 10.1016/j.jacc.2006.07.059.
• 22 Kayser SC, Dekkers T, Groenewoud HJ. et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: A systematic review and meta-regression analysis. J Clin Endocrinol Metab 2016; 101: 2826-2835 DOI: 10.1210/jc.2016-1472.
• 23 Buffolo F, Monticone S, Burrello J. et al. Is primary aldosteronism still largely unrecognized?. Horm Metab Res 2017; 49: 908-914 DOI: 10.1055/s-0043-119755.